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Aims We tested whether on-statin C-reactive protein is associated with cardiovascular (CV) outcome in the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT).
Methods
and results
ASCOT randomized a subset of 4853 patients with total cholesterol ≤6.5 mmol/L (250 mg/dL) to atorvastatin or
placebo. In a case–control study during 5.5-year follow-up, 485 CV cases were age- and sex-matched with 1367 con-
trols. Baseline LDL-cholesterol (LDL-c) and log-transformed C-reactive protein predicted CV events [odds ratio (OR)
per 1 standard deviation (SD) 1.31 (95% conﬁdence interval {CI}: 1.10, 1.56), P ¼ 0.002 and OR 1.19 (1.05, 1.34),
P ¼ 0.006, respectively]. Including baseline C-reactive protein into a Framingham risk model very modestly improved
risk prediction. Baseline C-reactive protein did not indicate the magnitude of the atorvastatin effect on CV outcome
(P ¼ 0.54). At 6 months, atorvastatin reduced median LDL-c by 40.3% and median C-reactive protein by 27.4%. In
those randomized to atorvastatin, lower on-treatment LDL-c at 6 months was associated with a signiﬁcant reduction
in subsequent CV events [OR 0.41 (0.22, 0.75), P ¼ 0.004] comparing those above and below the median (2.1 mmol/L).
In contrast, C-reactive protein below the median (1.83 mg/L) compared with C-reactive protein above the median was
not associated with a signiﬁcant reduction in CV events [OR 0.86 (0.49, 1.51), P ¼ 0.60]. Consequently, addition of on-
treatment C-reactive protein to LDL-c did not improve prediction of statin efﬁcacy.
Conclusion Among these hypertensive patients selected on the basis of traditional CV risk factors, C-reactive protein did not
usefully improve the prediction of CV events and, critically, reduction in C-reactive protein associated with statin
therapy was not a predictor of CV outcome alone or in combination with LDL-c.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Certain inﬂammatory markers, such as C-reactive protein, have
been shown to be associated with risk for cardiovascular (CV)
disease independent of classical risk markers, including
LDL-cholesterol (LDL-c).
1,2 In several trials, statin therapy has
been shown to lower circulating C-reactive protein.
3,4 In the
recent JUPITER (Justiﬁcation for the Use of statins in Prevention:
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which C-reactive protein is lowered by statins was reported to
predict CV outcomes independently of LDL-c lowering.
5 Indeed,
authors have argued that the JUPITER trial provides conﬁrmation
of the value of C-reactive protein in determining CV risk.
6 This
ﬁnding is at variance with data from existing meta-analyses,
which suggest that the ‘anti-inﬂammatory’ effect of statins may
be a secondary effect of LDL-c reduction and that LDL-c reduction
accounts for most of the beneﬁt of statins.
7,8 To further investigate
this controversial issue, we have conducted a nested case–control
study on participants recruited into ASCOT. Speciﬁcally, we tested
the hypotheses that (i) baseline C-reactive protein (i.e. prior to
randomization) is associated with and improves CV disease risk
prediction, (ii) that baseline C-reactive protein modiﬁes the efﬁ-
cacy of statins in reducing CV events, and (iii) that C-reactive
protein levels during statin use predict statin efﬁcacy independently
of LDL-c reduction.
Methods
A nested case–control study based on the ASCOT-Blood Pressure-
Lowering Arm (BPLA) cohort was used to determine the association
of baseline C-reactive protein with subsequent events. In a separate
analysis, the ASCOT-Lipid-Lowering Arm (LLA) subgroup was used
to assess whether C-reactive protein levels following 6-month treat-
ment with atorvastatin 10 mg was an independent predictor of CV
outcomes.
For the purpose of the present study, those with any history of CV
disease were excluded.
Patients and recruitment
The detailed ASCOT protocol has been published previously
9 and
further information is available at http://www.ascotstudy.org. Hyper-
tensive patients, with three or more other risk factors for cardiovascu-
lar disease but no history of prior myocardial infarction or currently
treated angina, were eligible.
In ASCOT-BPLA, in the UK and Ireland, 9098 patients were ran-
domized to either amlodipine adding perindopril as required
(amlodipine-based) or atenolol adding bendroﬂumethiazide as
required (atenolol-based).
In addition to randomization into ASCOT-BPLA, those with a fasting
total cholesterol of ≤6.5 mmol/L (250 mg/dL) were further random-
ized, using a factorial design, to either 10 mg atorvastatin daily or
matching placebo (ASCOT-LLA).
ASCOT-LLA was stopped prematurely after a median follow-up of
3.3 years owing to highly signiﬁcant beneﬁts in favour of atorvastatin
over placebo on the primary coronary endpoint. All patients in
ASCOT-LLA were offered open-label atorvastatin and continued in
the ASCOT-BPLA until its termination after a median 5.5-year
follow-up.
Baseline characteristics of participants and primary outcomes of
each arm of the trial have been reported previously.
9–11
All events of fatal coronary heart disease (CHD), symptomatic non-
fatal myocardial infarction (MI), coronary revascularization, and fatal
and non-fatal stroke occurring in the UK and Ireland during the
ASCOT-BPLA study period between February 1998 and October
2005 were identiﬁed as cases. During the median follow-up period
of 5.5 years, 485 CV events (355 CHD and 130 strokes) were eligible
for case–control analyses. Controls were selected from the UK and
Ireland ASCOT study population who were alive at the time the
case was diagnosed and free from CV disease in the study period.
Up to three controls from the same risk set were matched to each
case by age (+1 year), sex, and study entry time +90 days. In
total, the 485 cases were matched to 1367 controls. Of the 4853 sub-
jects from UK and Ireland, who were randomized to either atorvastatin
or placebo in ASCOT-LLA, there were 235 cases and 777 controls
(Figure 1).
Laboratory methods
Fasting lipids were routinely measured during the trial (www.
ascotstudy.org). C-reactive protein samples were collected at baseline
and 6 months and subsequently all stored serum samples were
measured by a high-sensitivity method, on an Abbott Architect,
by technicians blinded to the case–control status of the samples.
The lower limit of sensitivity was 0.1 mg/L and coefﬁcient of
variation ,4%.
Statistical methods
Age-adjusted partial correlations between loge transformed baseline
C-reactive protein and baseline clinical characteristics were estimated.
The association between C-reactive protein and the risk of each of
CHD or stroke event was reported as an odds ratio (OR) obtained
from a conditional logistic regression model, ﬁrst by treating log-
transformed baseline C-reactive protein as a continuous variable
giving the odds of having an event per 1 SD change with 95% conﬁ-
dence intervals (CIs) and secondly, by categorizing C-reactive
protein into tertiles with the lowest as a reference. Three models
were used: Model 1: unadjusted; Model 2 (modiﬁed Framingham CV
risk factors): adjusted for current smoking status, diabetes mellitus,
left ventricular hypertrophy, baseline systolic blood pressure (SBP),
total cholesterol and HDL, randomized atorvastatin/placebo/not in
ASCOT-LLA, randomized atenolol/amlodipine; Model 3 (extended
CV risk factors): adjusted for Model 2 plus body mass index (BMI),
logetransformed fasting glucose, family history of CHD (FHCHD),
creatinine, and educational attainment. To examine the extent to
which log C-reactive protein predicted CV events, unconditional
logistic regression models with adjustment for age and sex were
used on Framingham-based (Model 2) with and without loge -
C-reactive protein; and the fully adjusted model (Model 3) with
and without loge C-reactive protein. Akaike’s information criterion
and the Bayes information criterion were used to assess global ﬁt
of these models (Models 2 and 3). We also performed
likelihood-ratio tests to evaluate whether the global model ﬁt
improved after the addition of loge C-reactive protein. Areas under
the receiver operator characteristic (AUROC) curve for Model
2+loge C-reactive protein and for Model 3+loge C-reactive
protein were calculated. Discrimination was assessed by the
AUROC curve. Model calibration was assessed with the Hosmer–
Lemeshow goodness-of-ﬁt test. We computed the net reclassiﬁcation
improvement (NRI), which compares the shifts in reclassiﬁed cat-
egories by observed outcome. The integrated discrimination
improvement (IDI) was also calculated.
12
To assess the role of on-treatment LDL-c and C-reactive protein in
determining the likely impact of statin on CV events, cases and controls
assigned atorvastatin in ASCOT-LLA were divided into two groups
according to whether or not their on-treatment LDL-c was less than
or more than the median value achieved at 6-month in-trial. A
similar analysis was performed after subdividing on the basis of being
above or below the median achieved C-reactive protein. These
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(Figure 1). A multiple conditional logistic regression model (Model 3)
was used to estimate ORs for CV events in these groups compared
with the placebo group. A similar analysis was performed after subdi-
viding into two groups on the basis of being above or below the
median achieved C-reactive protein. Subjects with an event which
occurred before the on-treatment C-reactive protein or LDL-c
blood sample was obtained were excluded from these analyses.
In order to investigate the effect of the on-treatment C-reactive
protein across the categories of on-treatment LDL-c, the above
process was repeated after dividing the subjects allocated atorvastatin
into four groups on the basis of the LDL-c cut-off value and the
C-reactive protein cut-off value. For comparison with data derived
from the recently reported JUPITER trial,
5 we also repeated the ana-
lyses using the cut-off values for LDL-c (1.8 mmol/L) and C-reactive
protein (1 and 2 mg/L).
Sensitivity analyses were performed on data restricted to patients
with baseline C-reactive protein of ,3 SDs. Two-sided P-values of
≤0.5 were considered statistically signiﬁcant. All statistical analyses
were performed with SAS V9.1 (SAS Institute, Cary, NC, USA) and
STATA V11 (STATA Corporation, College Station, TX, USA).
Results
Baseline characteristics
During a median follow-up period of 5.5 years [inter-quartile range
(IQR): 5.0, 6.0], a total of 1852 cases and controls were eligible for
inclusion in these analyses. Of these, 131 were excluded for
missing values of baseline C-reactive protein or covariates used
in the models (Figure 1). The mean age was 64.7+7.7 years and
84.7% were male. A comparison of the baseline characteristics
between cases and controls showed that cases had a generally
worse clinical proﬁle than the controls (Table 1).
Figure 1 ASCOT C-reactive protein nested case–control trial proﬁle.
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cardiovascular events in follow-up
Baseline C-reactive protein was associated with baseline LDL-c
(r ¼ 0.11, P , 0.0001) among cases and controls combined.
C-reactive protein showed a direct linear association with the
risk of CHD and stroke combined and CHD alone but not with
stroke. The ORs for CV disease, CHD, and stroke were 1.19
(95% CI: 1.05, 1.34; P ¼ 0.006), 1.23 (1.06, 1.42; P ¼ 0.005) and
1.06 (0.82, 1.37; P ¼ 0.64) per 1 SD increase in loge-transformed
C-reactive protein, respectively, after adjusting for extensive CV
risk factors (Model 3; Table 2). Similar results were found when
analysing by tertiles of C-reactive protein (although only the com-
bined CHD and stroke endpoint showed signiﬁcant associations)
(Table 2).
Predictive ability of baseline C-reactive
protein in cardiovascular disease
prediction beyond classical risk factors
There was no signiﬁcant difference in the AUROC curve in either
the modiﬁed Framingham model (Model 2) (P ¼ 0.2), or the fully
adjusted Model 3 (P ¼ 0.18), after addition of C-reactive protein
(see Supplementary material online, Table S1). The Hosmer–
Lemeshow test indicated that C-reactive protein did not improve
calibration of either model.
We then considered the NRI across risk categories (see Sup-
plementary material online, Table S2). In 485 subjects who experi-
enced events, the Framingham model with C-reactive protein
increased (improved) risk category classiﬁcation in 54 subjects
but decreased classiﬁcation in 39, a net improvement in reclassiﬁ-
cation of +3.3%. In 1367 subjects who did not experience an
event, the model with C-reactive protein reclassiﬁed 131 increased
(worsened) risk categories and 116 decreased risk categories, a net
worsening in reclassiﬁcation of 1.2%. The NRI for the model
including C-reactive protein over the model without C-reactive
protein was therefore estimated to be 2.1% (P ¼ 0.32). Similar
results were obtained in the fully adjusted model (Model 3).
The estimate of IDI was then assessed. There was a small
increase in the IDI of 0.38% (P ¼ 0.015) in Model 2, and 0.49%
(P ¼ 0.013) in the fully adjusted Model 3 when C-reactive
protein was included.
Baseline C-reactive protein and outcome
in the on-statin group
There was no evidence of an interaction between baseline LDL-c
or C-reactive protein and treatment effect (statin/placebo or ate-
nolol/amlodipine-based) on CV events. The statin effect did not
differ according to the tertile of baseline C-reactive protein,
despite the lowest tertile having a somewhat greater beneﬁt
(Table 3).
Atorvastatin reduced the median LDL-c at 6 months by 40.3%
[from 3.55 mmol/L IQR: (2.98, 4.01) to 2.12 mmol/L (1.75,
2.52)], while in the placebo group, the median fell by 2% [from
3.44 mmol/L (2.99, 4.00) to 3.37 mmol/L (2.87, 3.87); comparing
change, P , 0.0001]. The concomitant changes for C-reactive
protein were a 27.4% reduction on atorvastatin [from 2.52 mg/L
(1.27, 5.02) to 1.83 mg/L (0.91, 3.62)] and a 6% increase on
placebo [from 2.43 mg/L (1.21, 4.90) to 2.57 mg/L (1.39, 5.02);
P , 0.0001]. This on-treatment change in C-reactive protein was
independent of baseline classical risk factors, baseline C-reactive
protein, and change in LDL-c (P ¼ 0.02). In ASCOT-LLA, in
those assigned atorvastatin, age-adjusted Spearman’s correlation
between percentage change in C-reactive protein and percentage
change in LDL was modest (r ¼ 0.19 P ¼ 0.0006).
Baseline proﬁles of statin recipients who
did and did not achieve 6-month
C-reactive protein or LDL-c levels below
the median
Despite reduction in C-reactive protein being independent of
baseline classical risk factors, there were baseline differences in
................................................................................
Table 1 Baseline characteristics of study population
Variable Cases
(n 5 485)
Controls
(n 5 1367)
P-value
Male 409 (84.3%) 1159 (84.8%) 0.81
Age (years) 64.80 (7.83) 64.65 (7.66) 0.71
Current smokers 127 (26.2%) 297 (21.7%) 0.04
Alcohol
Never 124 (25.6%) 298 (21.8%)
≤14/21 U/week 270 (55.7%) 803 (58.7%)
.14/21 U/week 91 (18.8%) 266 (19.5%) 0.23
Completed education 182 (37.5%) 452 (33.1%)
Age: ≤15 233 (48.0%) 632 (46.2%)
Age: ≤18 46 (9.5%) 154 (11.3%)
Age: 19+ 24 (4.9%) 129 (9.4%) 0.007
SBP (mmHg) 164.61
(17.81)
161.70 (17.48) 0.002
DBP (mmHg) 92.95 (10.37) 92.13 (9.83) 0.12
Heart rate (b.p.m.) 69.65 (12.91) 70.35 (11.85) 0.28
BMI (kg/m
2) 28.71 (4.05) 29.00 (4.50) 0.21
Total cholesterol
(mmol/L)
5.99 (1.07) 5.92 (1.07) 0.21
LDL-c (mmol/L) 3.92 (0.97) 3.79 (0.96) 0.02
HDL-cholesterol
(mmol/L)
1.26 (0.33) 1.30 (0.34) 0.02
Loge triglyceride
(mmol/L)
0.52 (0.46) 0.50 (0.49) 0.44
Loge C-reactive
protein (mg/L)
1.13 (0.98) 0.95 (0.98) 0.0006
Loge glucose (mmol/L) 1.82 (0.31) 1.78 (0.28) 0.03
Creatinine (mmol/L) 102.34
(19.31)
99.23 (16.57) 0.0008
Diabetes 150 (30.9%) 356 (26.0%) 0.038
Family history CHD 85 (17.5%) 233 (17.0%) 0.81
Amlodipine 227 (46.8%) 694 (50.8%) 0.13
Atorvastatin
a 101 (43.0%) 407(52.4%) 0.01
Values are mean (SD) or n (%). Missing: LDL-c, 121; triglycerides, 79; fasting
glucose, 84; creatinine, 45; C-reactive protein, 4.
aTwo hundred and thirty-ﬁve cases and 777 controls participated in lipid-lowering
arm.
Evaluation of C-reactive protein prior to and on-treatment 489statin recipients based on achieved C-reactive protein above and
below 1.83 mg/L. Those not achieving this C-reactive protein con-
centration had a higher baseline C-reactive protein, were more
commonly smokers, had around a 2 U higher BMI, a far greater
prevalence of diabetes, and family history of CHD, as well as
higher triglycerides (see Supplementary material online, Table
S3). Statin recipients who did achieve lower LDL-c values were
broadly similar to those who did not, other than a higher baseline
cholesterol level and a slight age difference (see Supplementary
material online, Table S4).
Six-month reduction in LDL-cholesterol
and C-reactive protein and risk of
cardiovascular events in ASCOT-LLA
Compared with placebo, subjects allocated to atorvastatin who did
not achieve an LDL-c of ,2.1 mmol/L (median value, atorvastatin
group) did not have a lower risk of CV disease [OR 1.10 (0.69–
1.76); Table 4]. However, there was a 55% reduction in the risk
of CV events in those who did achieve a reduction in LDL-c to
,2.1 mmol/L [OR 0.45 (0.27–0.77); P ¼ 0.003] in the
multivariable-adjusted Model 3. Consequently, CV event risk was
...............................................................................................................................................................................
Table 2 Odds ratios (95% conﬁdence interval) of cardiovascular event (coronary heart disease or stroke) in relation to
baseline C-reactive protein (per standard deviation increase in log-transformed C-reactive protein and in C-reactive
protein tertiles)
Cases/
controls
Model 1 P-value Model 2 P-value Model 3 P-value
CHD or stroke
Per 1 SD increase in loge C-reactive protein 452/1269 1.21 (1.09,1.35) 0.0004 1.16 (1.04,1.30) 0.009 1.19 (1.05,1.34) 0.006
Tertile 1 C-reactive protein: ,1.74 mg/L 131/448 1.00 (ref) 1.00 (ref) 1.00 (ref)
Tertile 2 C-reactive protein: 1.74–4.09 mg/L 153/417 1.26 (0.97,1.64) 0.08 1.16 (0.88,1.51) 0.29 1.25 (0.93,1.67) 0.14
Tertile 3 C-reactive protein: .4.09 mg/L 168/404 1.45 (1.12,1.89) 0.005 1.30 (0.99,1.70) 0.06 1.35 (1.00,1.82) 0.05
Trend 0.005 0.057 0.05
CHD Only
Per 1 SD increase in loge C-reactive protein 331/939 1.26 (1.11,1.42) 0.0003 1.19 (1.04,1.35) 0.009 1.23 (1.06,1.42) 0.005
Tertile 1 C-reactive protein: ,1.74 mg/L 87/330 1.00 (ref) 0.02 1.00 (ref) 0.14 1.00 (ref)
Tertile 2 C-reactive protein: 1.74–4.09 mg/L 119/310 1.43 (1.05,1.94) 0.024 1.28 (0.93,1.76) 0.13 1.35 (0.95,1.91) 0.09
Tertile 3 C-reactive protein: .4.09 mg/L 125/299 1.50 (1.10,2.04) 0.01 1.27 (0.92,1.75) 0.15 1.36 (0.95,1.94) 0.09
Trend 0.01 0.16 0.10
Stroke only
Per 1 SD increase in loge C-reactive protein 121/330 1.09 (0.88,1.34) 0.44 1.08 (0.86,1.36) 0.50 1.06 (0.82,1.37) 0.64
Tertile 1 C-reactive protein: ,1.74 mg/L 44/118 1.00 (ref) 1.00 (ref) 1.00 (ref)
Tertile 2 C-reactive protein: 1.74–4.09 mg/L 34/107 0.91 (0.55,1.50) 0.70 0.88 (0.52,1.50) 0.63 1.03 (0.57,1.87) 0.91
Tertile 3 C-reactive protein: .4.09 mg/L 43/105 1.38 (0.84,2.28) 0.20 1.37 (0.81,2.32) 0.25 1.36 (0.74,2.48) 0.32
0.22 0.24 0.32
Model 1: unadjusted. Model 2: adjusted for current smoking status, diabetes mellitus, randomized BP treatment (atenolol/amlodipine), randomized
atorvastatin/placebo/not in LLA, left ventricular hypertrophy, baseline SBP, total cholesterol, and HDL-cholesterol. Model 3: adjusted as for in Model 2 plus BMI, loge glucose,
family history of CHD, creatinine, and educational attainment.
............................................................................................................................................
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Table 3 Atorvastatin effect by tertile of baseline C-reactive protein
ORs (95% CI) by tertile of baseline C-reactive protein
Low <1.74 mg/L Middle 1.74–4.09 mg/L High >4.09 mg/L Interaction
a
Case/control 67/259 72/239 80/219
CHD or stroke 0.74 (0.38, 1.45) 0.81 (0.42, 1.57) 1.09 (0.56, 2.14) 0.70
Adjusted for current smoking status, diabetes mellitus, randomized BP treatment (atenolol/amlodipine), randomized atorvastatin/placebo, left ventricular hypertrophy, baseline
SBP, total cholesterol, HDL- cholesterol, BMI, loge-glucose, family history of CHD, creatinine, and educational attainment.
aInteraction between statin treatment and tertile baseline C-reactive protein.
P.S. Sever et al. 490reduced by 59% in those whose LDL-c reduction was less than
compared with those greater than the median [OR 0.41 (0.22–
0.75)]. In contrast, those who achieved C-reactive protein below
the median did not have a signiﬁcantly reduced risk of CV events
relative to those who did not [OR 0.86 (0.49–1.51)]. The effects
of percentage change in LDL-c and C-reactive protein on CV
events showed only borderline signiﬁcance for LDL-c change and
no association with C-reactive protein change (see Supplementary
..........................................................................................................
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Table 4 Odds ratios (95% conﬁdence interval) for cardiovascular (coronary heart disease or stroke) events in relation
to achieved (6-month in-trial) and median reductions in LDL-c and C-reactive protein
Cases/controls Model 1 P-value Model 2 P-value Model 3 P-value
Target lipid or C-reactive protein concentration
Lipid
Placebo 89/232 1 (ref.) 1 (ref.) 1 (ref.)
Atorvastatin
LDL ≥2.1 mmol/L
a 44/126 0.97 (0.64, 1.46) 0.87 1.09 (0.70, 1.67) 0.71 1.10 (0.69, 1.76) 0.68
LDL ,2.1 mmol/L
a 23/140 0.45 (0.27, 0.73) 0.001 0.45 (0.27, 0.76) 0.003 0.45 (0.27, 0.77) 0.003
LDL ,2.1 vs. ≥2.1 mmol/L 0.40 (0.22, 0.71 0.002 0.41 (0.23, 0.74) 0.003 0.41 (0.22, 0.75) 0.004
C-reactive protein
Placebo 93/245 1 (ref.) 1 (ref.) 1 (ref.)
Atorvastatin
C-reactive protein ≥1.83 mg/L
a 41/137 0.86 (0.58, 1.29) 0.47 0.83 (0.54, 1.27) 0.39 0.82 (0.52, 1.28) 0.38
C-reactive protein ,1.83 mg/L
a 32/140 0.61 (0.39, 0.94) 0.03 0.71 (0.45, 1.12) 0.14 0.70 (0.44, 1.13) 0.15
C-reactive protein
,1.83 vs. ≥1.83 mg/L
0.70 (0.43, 1.16) 0.17 0.86 (0.50, 1.46) 0.56 0.86 (0.49, 1.51) 0.60
Model 1: unadjusted. Model 2: adjusted for baseline LDL cholesterol and loge baseline C-reactive protein. Model 3: current smoking status, diabetes mellitus, randomized BP
treatment (atenolol/amlodipine), left ventricular hypertrophy, baseline SBP, HDL-cholesterol, BMI, loge-glucose, family history of CHD, creatinine, educational attainment,
baseline LDL-c or total cholesterol, and loge baseline C-reactive protein.
aMedian LDL and C-reactive protein concentrations in the atorvastatin group.
Figure 2 Odds ratios for incident cardiovascular events according to achieved LDL-cholesterol and C-reactive protein after 6 months on
atorvastatin. LDL-cholesterol achieved in mmol/L and C-reactive protein in mg/L. Adjusted for current smoking status, diabetes mellitus, ran-
domized blood pressure treatment (atenolol/amlodipine), randomized atorvastatin/placebo/not in lipid-lowering arm, left ventricular hypertro-
phy, baseline systolic blood pressure, total cholesterol, HDL, body mass index, log-glucose, family history of coronary heart disease, creatinine
and educational attainment, baseline LDL or total cholesterol, and log baseline C-reactive protein.
Evaluation of C-reactive protein prior to and on-treatment 491material online, Table S5). The risk of CHD events was much lower
in those who achieved the LDL-c level below the median at 6
months (see Supplementary material online, Table S6). There was
little change in these results when restricted to those with a base-
line C-reactive protein of ,3 SD (see Supplementary material
online, Tables S7 and S8).
There was no clear evidence that the achievement of various
‘target’C-reactiveproteinlevelsaftertheLDL-ctargetwasachieved,
resulted in any further reduction in risk using a number of models
(Figure 2 and Table 5). For instance, if LDL-c was lowered to
,2.1 mmol/L but C-reactive protein remained above the median
(1.83 mg/L), the risk of CV events was reduced by 57% relative to
placebo. In contrast if both LDL-c and C-reactive protein achieved
the ‘target’, the risk of CV events was reduced 51% relative to
placebo (Table 5). Similar trends were also noted for the LDL-c
and C-reactive protein cut-offs presented in JUPITER. Similar ﬁnd-
ings were also observed when only CHD events were considered
(see Supplementary material online, Table S9).
Discussion
In ASCOT, subjects were recruited on the basis of conventional
risk factors and, although atorvastatin lowered C-reactive protein
by 27% over 6 months in trial, neither baseline C-reactive
protein nor C-reactive protein on-treatment with atorvastatin
related to the magnitude of statin efﬁcacy in the prevention of
CV events, whereas, as expected, on-treatment LDL-c was
strongly predictive. These results are important as they enrich
the evidence base on a topical issue relevant to clinical practice.
In ASCOT, the lack of association of baseline C-reactive protein
with statin-associated relative CVD risk reduction is not contro-
versial. Indeed, the recently reported large data set from the
Heart Protection Study
13 and the previously reported
PROSPER
14 and JUPITER
15 studies all concur on this aspect.
However, in ASCOT, our observation that on-statin C-reactive
protein was not associated with CV outcomes does differ from
results reported by JUPITER and PROVE IT-TIMI 22.
5,16 Given
these discrepancies, it is important to consider underlying differ-
ences between the trials. First, PROVE IT-TIMI 22 recruited high-
risk patients with proven CHD.
17 JUPITER recruited apparently
healthy men and women (aged .50 and 60 years, respectively)
with low LDL-c , 3.4 mmol/L (,130 mg/dL) [median at ran-
domization, 2.8 mmol/L (107 mg/dL)] but an elevated C-reactive
protein ≥2 mg/L (median at randomization 4.3 mg/L).
5 Men and
women recruited into ASCOT (aged 40–79 years) had no pre-
vious history of CHD, but did have three or more prevalent clas-
sical CV risk factors and hypertension. Eligibility for ASCOT-LLA
required a total cholesterol of ≤6.5 mmol/L (≤250 mg/dL)
[median LDL-c at randomization 3.8 mmol/L (145 mg/dL)]. The
median C-reactive protein at randomization into ASCOT was
2.7 mg/L (IQR: 1.4, 5.2).This compares with pooled data from 54
observational studies where the median C-reactive protein was
1.72 mg/L (95% CI: 0.25–12.4).
18 Second, JUPITER outcomes
were a combination of hard and soft outcomes (10.9% of
primary endpoints in JUPITER were from hospitalization for
unstable angina events), whereas the present study is based on
hard outcomes only. Third, the type and equivalent dose of
statin used in JUPITER was different and higher than that in
ASCOT (rosuvastatin 20 mg vs. atorvastatin 10 mg), although
...............................................................................................................................................................................
Table 5 Odds ratios (95% conﬁdence interval) for cardiovascular events (coronary heart disease or stroke) in relation
to achieved concentrations at 6-month in-trial of both cholesterol and C-reactive protein in subjects allocated to
atorvastatin
Cases/controls Odds ratios P-value
Placebo (ref.) 88/230 1.00 (ref.)
(ASCOT medians)
LDL ≥2.1 and C-reactive protein ≥1.83 27/65 1.28 (0.72, 2.26) 0.40
LDL ≥2.1 and C-reactive protein ,1.83 17/55 0.99 (0.52, 1.88) 0.98
LDL ,2.1 and C-reactive protein ≥1.83 11/62 0.43 (0.21, 0.88) 0.02
LDL ,2.1 and C-reactive protein ,1.83 12/76 0.49 (0.25, 0.99) 0.05
(JUPITER cut-offs)
LDL ≥1.8 and C-reactive protein ≥2 30/81 1.05 (0.61, 1.81) 0.85
LDL ≥1.8 and C-reactive protein ,2 27/94 0.93 (0.55, 1.59) 0.80
LDL ,1.8 and C-reactive protein ≥2 3/36 0.21 (0.06, 0.71) 0.01
LDL ,1.8 and C-reactive protein ,2 7/47 0.42 (0.17, 1.02 0.06
(JUPITER cut-offs)
LDL ≥1.8 and C-reactive protein ≥1 46/126 1.08 (0.68, 1.72) 0.75
LDL ≥1.8 and C-reactive protein ,1 11/49 0.76 (0.36, 1.60) 0.48
LDL ,1.8 and C-reactive protein ≥1 5/53 0.23 (0.08, 0.61) 0.003
LDL ,1.8 and C-reactive protein ,1 5/30 0.53 (0.19, 1.48) 0.23
LDL-cholesterol in mmol/L and C-reactive protein in mg/L. Adjusted forcurrent smoking status, diabetes mellitus, randomized BP treatment (atenolol/amlodipine), left ventricular
hypertrophy, baseline SBP, total cholesterol, HDL-cholesterol, BMI, loge-glucose, family history of CHD, creatinine, educational attainment, baseline LDL or total cholesterol, and
loge baseline C-reactive protein.
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C-reactive protein (37 vs. 27%, respectively) were broadly com-
parable. Fourth, the study designs were different—ASCOT was a
nested case–control study, whereas JUPITER and PROVE
IT-TIMI 22 were cohort studies.
It has been argued that since statins lower both C-reactive
protein and LDL-c, it is difﬁcult to distinguish whether
reductions in risk observed are due to LDL-c lowering,
C-reactive protein lowering, or some combination.
19 This is
the case even among people starting with low LDL-c (such as
JUPITER) because of the log-linear association of LDL-c with
vascular risk over the whole range,
20 which suggests that a ben-
eﬁcial effect of LDL-c lowering is likely irrespective of the base-
line LDL-c.
Our ﬁndings are clinically important, since the ASCOT-LLA
patient group is likely to represent a more typical population con-
sidered at risk of CV events than JUPITER and thus would more
often be candidates for lipid-lowering therapy. Cardiovascular
event rates were higher in ASCOT than JUPITER (for myocardial
infarction 7.9 vs. 3.7 and stroke 5.4 vs. 3.4 per 1000 patient-years,
respectively) and all-cause mortality 15.1 vs. 12.5 per 1000 patient-
years, respectively). However, absolute risk reduction from statin
use in the two trials was broadly similar (for myocardial infarction
2.7 vs. 2.0 and for stroke 1.5 vs. 1.6 per 1000 patient-years in
ASCOT and JUPITER, respectively). JUPITER investigators have
also recently reported that the baseline use of C-reactive
protein adds clinical utility to risk prediction among those with
low LDL-c and high C-reactive protein.
21 Our results suggest
that any incremental clinical utility of baseline C-reactive protein
in identifying those at risk of future CV events, in addition to Fra-
mingham, is likely to be at best modest among the relatively typical
hypertensive patients recruited into ASCOT. The IDI improved
,0.5% when C-reactive protein was added to a Framingham
model. These ﬁndings are broadly in line with other prospective
studies showing statistically signiﬁcant, but modest absolute
improvements with the use of C-reactive protein in clinical risk
prediction.
22,23
Limitations of our study require consideration. The choice of
LDL-c and C-reactive protein cut-offs is somewhat arbitrary. We
studied medians and the pre-speciﬁed cut-offs reported by
JUPITER; overall results by different cut-offs are broadly consist-
ent, reducing the possibility that the selection of cut-offs has
biased our results. Some of the comparisons of event incidence
in subgroups by LDL-c and C-reactive protein cut-offs have
modest numbers of events, although the number of events in
the present study are broadly comparable to JUPITER. Although
we used a case–control design, case–control analyses result in
only very small reduction in power in a study of this size.
24
ASCOT-LLA participants were followed for events beyond the
duration of this arm of the overall trial, although this would not
be expected to affect the efﬁcacy of the statin therapy (risk
reductions in the statin arm were the same at 3.3- and 5.5-year
follow-up).
25 Sensitivity analyses, restricting events to those occur-
ring during the 3.3 years of the LLA arm of the trial, were similar
to those reported here. In addition, the association of C-reactive
protein with CV risk is broadly as expected from other prospec-
tive studies.
2
In conclusion, we ﬁnd that in this hypertensive population
selected on the basis of traditional common coexisting risk
factors, C-reactive protein did not usefully improve the prediction
of CV events and, critically, reduction in C-reactive protein associ-
ated with statin therapy was not a predictor of CV outcome.
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